However, it must be aware that combined using immunotherapy and anti-angiogenic therapy targeting VEGF or VEGFR may be not effective in certain conditions, because it has been indicated that VEGF inhibition is not beneficial in some human solid tumor types (NSABP-C-08; clinicaltrials.gov: NCT00096278) and even results in progression in certain cancer types (reviewed in [102, 103]). This evidence concerns the gene VEGFA and cancer.